Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy

EC Morris, SS Neelapu, T Giavridis… - Nature Reviews …, 2022 - nature.com
A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …

Next generation of immune checkpoint inhibitors and beyond

JA Marin-Acevedo, EMO Kimbrough, Y Lou - Journal of hematology & …, 2021 - Springer
The immune system is the core defense against cancer development and progression.
Failure of the immune system to recognize and eliminate malignant cells plays an important …

Role of glutathione in cancer: from mechanisms to therapies

L Kennedy, JK Sandhu, ME Harper, M Cuperlovic-Culf - Biomolecules, 2020 - mdpi.com
Glutathione (GSH) is the most abundant non-protein thiol present at millimolar
concentrations in mammalian tissues. As an important intracellular antioxidant, it acts as a …

Roles of IL-1 in cancer: from tumor progression to resistance to targeted therapies

V Gelfo, D Romaniello, M Mazzeschi, M Sgarzi… - International journal of …, 2020 - mdpi.com
IL-1 belongs to a family of 11 members and is one of the seven receptor-agonists with pro-
inflammatory activity. Beyond its biological role as a regulator of the innate immune …

Mast cells: A new frontier for cancer immunotherapy

JN Lichterman, SM Reddy - Cells, 2021 - mdpi.com
Mast cells are unique tissue-resident immune cells of the myeloid lineage that have long
been implicated in the pathogenesis of allergic and autoimmune disorders. More recently …

A paracrine circuit of IL-1β/IL-1R1 between myeloid and tumor cells drives genotype-dependent glioblastoma progression

Z Chen, B Giotti, M Kaluzova… - The Journal of …, 2023 - Am Soc Clin Investig
Monocytes and monocyte-derived macrophages (MDMs) from blood circulation infiltrate
glioblastoma (GBM) and promote growth. Here, we show that PDGFB-driven GBM cells …

Emerging targeted therapies in advanced non-small-cell lung cancer

S Li, GS de Camargo Correia, J Wang, R Manochakian… - Cancers, 2023 - mdpi.com
Simple Summary The discovery of actionable oncogenic driver mutations in non-small-cell
lung cancer (NSCLC) has revolutionized the treatment and prognosis of this dreadful …

Divergent functions of NLRP3 inflammasomes in cancer: a review

A Shadab, M Mahjoor, M Abbasi-Kolli… - Cell Communication and …, 2023 - Springer
The cancer is a serious health problem, which is The cancer death rate (cancer mortality) is
158.3 per 100,000 men and women per year (based on 2013–2017 deaths). Both clinical …

The role of IL-1 family of cytokines and receptors in pathogenesis of COVID-19

S Makaremi, A Asgarzadeh, H Kianfar… - Inflammation …, 2022 - Springer
A global pandemic has erupted as a result of the new brand coronavirus, severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). This pandemic has been consociated …

Inflammation as a driver of prostate cancer metastasis and therapeutic resistance

M Archer, N Dogra, N Kyprianou - Cancers, 2020 - mdpi.com
Simple Summary Prostate cancer is the most common malignancy in men, with a high
mortality rate when disease progresses to metastasis and therapeutic resistance. Evidence …